Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Researchers are using artificial intelligence to reduce the dose of a contrast agent that may be left behind in the body after MRI exams, according to a new study. Researchers are using artificial ...

Qualitative ratings showed non-significant differences between the proposed method – a 10% level of gadolinium dose – and acquired full-dose contrast-enhanced MRI images, which was also verified with ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Simulations reveal details about the magnetic interactions between gadolinium contrast agents used in MRI scans and their environment. You can keep your best guesses. Engineers at Rice University's ...

A new study has shown that artificial intelligence could be used to dramatically reduce the amount of gadolinium used in MRI scans. The findings, which are being presented today at the annual meeting ...

January 2, 2007 — The US Food and Drug Administration (FDA) warned healthcare professionals last week about additional reports of nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...

Physicians routinely prescribe an infusion containing gadolinium to enhance MRI scans, but there is evidence that nanoparticles of the toxic rare earth metal infiltrate kidney cells, sometimes ...

Clare Garrett was poisoned by contrast dye used for an MRI scan, and now she is in a wheelchair "90 percent of the time." The former runner says her "health has massively deteriorated," but she cannot ...

Study Overview: This ongoing Phase 4 study, officially titled “Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor ...

Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...

Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the ...